NO990433L - New compounds and compositions for the treatment of diseases associated with tryptase activity - Google Patents

New compounds and compositions for the treatment of diseases associated with tryptase activity

Info

Publication number
NO990433L
NO990433L NO990433A NO990433A NO990433L NO 990433 L NO990433 L NO 990433L NO 990433 A NO990433 A NO 990433A NO 990433 A NO990433 A NO 990433A NO 990433 L NO990433 L NO 990433L
Authority
NO
Norway
Prior art keywords
compositions
treatment
diseases associated
new compounds
tryptase activity
Prior art date
Application number
NO990433A
Other languages
Norwegian (no)
Other versions
NO990433D0 (en
Inventor
Jeffrey Mark Dener
Elaine Yee-Lin Kuo
Ken Duane Rice
Vivian Rueywen Wang
Wendy Beth Young
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of NO990433D0 publication Critical patent/NO990433D0/en
Publication of NO990433L publication Critical patent/NO990433L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Abstract

Foreliggende oppfinnelse angår nye forbindelser som er tryptaseinhibitorer; deres farmasøytisk akseptable salter og N-oksider; deres anvendelse som terapeutiske midler, samt fremgangsmåter for deres fremstilling.The present invention relates to novel compounds which are tryptase inhibitors; their pharmaceutically acceptable salts and N-oxides; their use as therapeutic agents, as well as methods of their preparation.

NO990433A 1996-07-30 1999-01-29 New compounds and compositions for the treatment of diseases associated with tryptase activity NO990433L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US89577297A 1997-07-17 1997-07-17
PCT/US1997/013422 WO1998004537A1 (en) 1996-07-30 1997-07-30 Novel compounds and compositions for treating diseases associated with tryptase activity

Publications (2)

Publication Number Publication Date
NO990433D0 NO990433D0 (en) 1999-01-29
NO990433L true NO990433L (en) 1999-03-25

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990433A NO990433L (en) 1996-07-30 1999-01-29 New compounds and compositions for the treatment of diseases associated with tryptase activity

Country Status (17)

Country Link
EP (1) EP0934293A1 (en)
JP (1) JP2001509787A (en)
KR (1) KR20000029679A (en)
CN (1) CN1073103C (en)
AU (1) AU733621B2 (en)
CA (1) CA2262542A1 (en)
CZ (1) CZ29799A3 (en)
EE (1) EE9900036A (en)
FI (1) FI990171A (en)
HU (1) HUP0003267A3 (en)
LV (1) LV12291B (en)
NO (1) NO990433L (en)
NZ (1) NZ333713A (en)
PL (1) PL331465A1 (en)
SI (1) SI9720047A (en)
SK (1) SK8599A3 (en)
WO (1) WO1998004537A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
AU2723099A (en) * 1998-02-06 1999-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
EP1060175B1 (en) * 1998-02-06 2004-11-17 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Tryptase inhibitors
JP2003524598A (en) * 1998-09-04 2003-08-19 アルタナ ファルマ アクチエンゲゼルシャフト New pyranocene
JP2003506442A (en) 1999-08-10 2003-02-18 アルタナ ファルマ アクチエンゲゼルシャフト Novel tryptase inhibitor
CA2384763A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (en) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basic compounds as tryptase inhibitors, process for their preparation and their use as medicaments
CA2392121A1 (en) * 1999-12-20 2001-06-28 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
TR200402164T4 (en) 1999-12-20 2004-10-21 Altana Pharma Ag Tryptase inhibitors
PT1358182E (en) * 2001-01-31 2004-12-31 Altana Pharma Ag DERIVATIVES OF DIAZOCINES AND THEIR USE AS TRIPTASE INHIBITORS
ATE364037T1 (en) 2001-02-21 2007-06-15 Altana Pharma Ag TRYPTASE INHIBITORS
EP1368317B1 (en) 2001-02-21 2006-12-27 Altana Pharma AG Tryptase inhibitors
CA2440482A1 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA03011566A (en) 2001-06-11 2004-10-28 Xenoport Inc Orally administered dosage forms of gaba analog prodrugs having reduced toxicity.
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US6962941B2 (en) 2001-06-19 2005-11-08 Altana Pharma Ag Tryptase inhibitors
NZ554737A (en) 2004-11-04 2011-04-29 Xenoport Inc Gabapentin prodrug sustained release oral dosage forms
TWI432188B (en) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of inflammatory skin diseases
CN102159201A (en) * 2008-12-19 2011-08-17 莫茨药物股份两合公司 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
FR3038605B1 (en) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne VICINAL PRIMARY DIAMINS ASSOCIATED WITH CHELATING MOTIFS OF METALS AND / OR FREE RADICALS, ACTIVE AGAINST CARBONYL AND OXIDIZING STRESSES AND THEIR USE
AU2018266393A1 (en) * 2017-05-12 2019-12-19 Riken Class A GPCR-binding compound modifier

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
UA42719C2 (en) * 1993-03-12 2001-11-15 Аксіз Фармасьютікелз, Інк Compositions and methods for the treatment of immunomediated inflammatory disorders
NZ263084A (en) * 1993-03-12 1997-08-22 Arris Pharm Corp Dipeptide derivatives, treatment of immunomediated inflammatory disorders
JPH10501238A (en) * 1994-06-01 1998-02-03 アリス ファーマシューティカル コーポレイション Compositions and methods for treating mast cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition
EP0817778A1 (en) * 1995-03-24 1998-01-14 Arris Pharmaceutical Corporation Reversible protease inhibitors
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Also Published As

Publication number Publication date
CA2262542A1 (en) 1998-02-05
PL331465A1 (en) 1999-07-19
LV12291A (en) 1999-06-20
HUP0003267A3 (en) 2002-02-28
NZ333713A (en) 2000-12-22
HUP0003267A2 (en) 2001-06-28
EE9900036A (en) 1999-08-16
WO1998004537A1 (en) 1998-02-05
LV12291B (en) 2000-04-20
SK8599A3 (en) 2000-03-13
EP0934293A1 (en) 1999-08-11
CZ29799A3 (en) 1999-06-16
JP2001509787A (en) 2001-07-24
FI990171A (en) 1999-03-23
NO990433D0 (en) 1999-01-29
KR20000029679A (en) 2000-05-25
FI990171A0 (en) 1999-01-29
CN1073103C (en) 2001-10-17
AU733621B2 (en) 2001-05-17
SI9720047A (en) 1999-08-31
AU3967097A (en) 1998-02-20
CN1226892A (en) 1999-08-25

Similar Documents

Publication Publication Date Title
NO990433L (en) New compounds and compositions for the treatment of diseases associated with tryptase activity
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
NO20021328L (en) Pyrazolopyrimidia as therapeutic agents
NO20012977D0 (en) N-ureidoalkylpiperidines as modulators of chemokine receptor activity
NO20093464L (en) New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics
SE0202462D0 (en) Novel use
DK1178958T3 (en) N-cyanomethylamides as protease inhibitors
MXPA02012712A (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity.
NO992400L (en) New substituted pyrazole derivatives
NO991732L (en) New heterocyclylmethyl substituted pyrazole derivatives
NO20051263L (en) New use of benzothiazole derivatives
ATE302606T1 (en) N-UREIDOALKYLPIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
BR0109211A (en) 5-ht1a Activity Compounds Useful for Treatment of External Retinal Disorders
NO963731L (en) Treatment of obsessive-compulsive diseases with 5HT2 antagonists
NO20014529D0 (en) Tetrahydropyran derivatives and their use as therapeutic agents
NO20073113L (en) Indenyl derivatives and their use for the treatment of neurological disorders
DK0888271T3 (en) Benzamidine derivatives substituted with amino acid and hydroxy acid derivatives and their use as anticoagulants
ATE251139T1 (en) (+)-NORCISAPRIDE USED FOR 5-HT3 AND 5-HT4 RELATED DISEASES
NO20016201L (en) Tienopyrimidines as phosphodiesterase inhibitors
DE60031686D1 (en) PYRAZINONE, COMPOSITIONS CONTAINING THESE COMPOUNDS
NO982863L (en) New compounds with analgesic effect
BR0317289A (en) Method for treating movement disorders using barbituric acid derivatives
WO2000076500A8 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
DK0767783T3 (en) Substituted alkyl diamine derivatives and their use as tachykinin antagonists
BRPI0415546A (en) compound, pharmaceutical composition, use of a compound, and methods of treatment or prophylaxis of human diseases or conditions, and disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application